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Abstract.  Integrin Otv~3 is distinct in its capacity to rec- 
ognize the sequence Arg-Gly-Asp (RGD) in many ex- 
tra-cellular matrix (ECM) components. Here, we dem- 
onstrate that in addition to the recognition of ECM 
components, ave3 can interact with the neural cell ad- 
hesion molecule L1-CAM; a member of the immuno- 
globulin superfamily (IgSF). M21 melanoma cells dis- 
played significant Ca++-dependent adhesion and 
spreading on immunopurified rat L1 (NILE). This ad- 
hesion was found to be dependent on the expression of 
the Otv-integrin subunit and could be significantly  inhib- 
ited by an antibody to the av~33 heterodimer. M21 cells 
also displayed some av133-dependent adhesion and 
spreading on immunopurified human L1. Ligation be- 
tween this ligand and e~vl33 was also observed to pro- 
mote significant haptotactic cell migration. 
To map the site of ~v~33 ligation we used recombinant 
L1 fragments comprising the entire extraceUular do- 
main of human L1. Significant av133-dependent adhe- 
sion and spreading was evident on a L1 fragment con- 
taining Ig-like domains 4, 5, and 6. Importantly, 
mutation of an RGD sequence present in the sixth Ig- 
like domain of L1 abrogated M21 cell adhesion. We 
conclude that av133-dependent recognition of human L1 
is dependent on ligation of this RGD site. 
Despite high levels of L1 expression the M21 mela- 
noma cells did not display significant adhesion via a ho- 
mophilic L1-L1 interaction. These data suggest that 
M21 melanoma cells recognize and adhere to L1 
through a mechanism that is primarily heterophilic and 
integrin dependent. Finally, we present evidence that 
melanoma cells can shed and deposit L1 in occluding 
ECM. In this regard, av133 may recognize L1 in a cell- 
cell or cell-substrate interaction. 
T 
HE neural cell adhesion molecule L1 is a multido- 
main glycoprotein and a member of the IgSF (Moos 
et al, 1988). This cell  adhesion molecule (CAM)  1 
was first described in the mouse, but homologous mole- 
cules have now been reported in man, rat (NILE), chick 
(NgCAM, 8D9, G4), and Drosphila (neuroglian) (Grumet 
et al., 1984; Bock et al., 1985; Lemmon and McLoon, 1986; 
Mujoo et al., 1986). These Ll-related glycoproteins have 
an extracellular region that consists of six immunoglobulin 
(Ig)-like domains followed by five fibronectin type III-like 
repeats.  There is  a  single  transmembrane region that is 
linked to  a  short, highly conserved cytoplasmic  domain 
(Moos et al, 1988; Sonderegger and Rathjen, 1992). Con- 
siderable sequence homology has been found between the 
mammalian Ll-related CAMs. Thus, the deduced identity 
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between the amino acid sequences  of human and mouse 
L1 is 87%  (Reid and Hemperly, 1992), while the amino 
acid homology between rat and mouse L1 is 96%  (Miura 
et al., 1991). 
Reference to L1 as a neural CAM is based on its distri- 
bution on post-mitotic neurons of the central and periph- 
eral  nervous  systems  and  on  pre-  or  non-myelinating 
Schwann cells of the peripheral nervous system (Lindner 
et  al.,  1983; Rathjen and  Schachner,  1984; Martini and 
Schachner,  1986). L1 has also been described on non-neu- 
ral ceils, including granulocytes, lymphocytes, and epithe- 
lial cells of the intestine and urogenital tract (Thor et al., 
1987; Kowitz et al., 1992; Kujat et al., 1995). This CAM is 
further expressed on transformed cells of diverse histolog- 
ical origin, including melanoma, neuroblastoma, embryo- 
nal carcinoma, osteogenic sarcoma, squamous lung carci- 
noma,  squamous  skin  carcinoma,  pheochromocytoma, 
rhabdomyosarcoma, and retinoblastoma cell lines (Mujoo 
et al., 1986; Linnemann et al., 1989; Reid and Hemperly, 
1992). Surprisingly,  despite widespread expression  of L1 
on many highly malignant tumors, little is known of the 
function of this CAM with respect to tumor progression 
© The Rockefeller University Press, 0021-9525/96/02/475/11  $2.00 
The Journal of Cell Biology, Volume 132, Number 3, February  1996 475~185  475 and dissemination. Linnemann et al. (1989) found L1 ex- 
pression on a metastatic variant of the melanoma cell line 
K1735, while nonmetastasizing cells were negative for this 
CAM,  suggesting a  role for this molecule in  tumor pro- 
gression. 
The Ll-related glycoproteins have been implicated in a 
variety of neurological processes,  including myelination, 
neurite fasiculation and outgrowth, and cerebellar cell mi- 
gration (Lindner et al., 1983; Martini and Schachner, 1986; 
Lagenaur and Lemmon, 1987). It is generally believed that 
L1 regulates these processes by virtue of a homophilic in- 
teraction i.e., L1-L1. However, it has recently been docu- 
mented that L1 can also interact with another member of 
the IgSF referred to as axonin-1/TAG 1 (Kuhn et al., 1991; 
Felsenfeld et al., 1994). Furthermore, it is conceivable that 
the large multidomain structure of L1 may facilitate fur- 
ther heterophilic interactions that remain to be identified. 
Integrin O~v[~3,  also known as the vitronectin receptor, is 
a transmembrane heterodimer consisting of noncovalently 
associated av and 133 glycoprotein subunits. The biological 
consequences of av[33 ligation are numerous and include 
the regulation of cell adhesion, morphology, migration, vi- 
ability, growth, and differentiation (Wayner et al.,  1991; 
Cheresh, 1992; Clyman et al., 1992; Leavesley et al., 1992). 
Regulation of these events and capacity for promiscuous 
ligand binding has placed av133 at the center of many fun- 
damental and important biological processes including an- 
giogenesis, wound  healing,  development, and  neoplastic 
progression (Cheresh, 1992; Brooks et al., 1994; Montgom- 
ery et al., 1994). One of the most important and distinctive 
features of av133 is its capacity to recognize the sequence 
Arg-Gly-Asp (RGD)  in  a  large number of extracellular 
matrix components. Significantly there are two such  se- 
quences in the sixth Ig-like domain of rat NILE/L1, while 
one of these sequences is conserved in man (Miura et al., 
1991). 
In  this  study we  demonstrate  that  in  addition  to  ho- 
mophilic L1-L1  interaction or heterophilic Ll-axonin-1/ 
TAG 1 interaction, L1 can also be recognized by the inte- 
grin C~vl33. Furthermore, we show that this novel interac- 
tion is dependent on the recognition of a conserved RGD 
site in the sixth Ig-like domain of human L1. We present 
further evidence that melanoma cells can deposit L1 in tu- 
mor-associated ECM raising the possibility that these tu- 
mor cells can modify their environment to promote etv133  li- 
gation. Cell-cell or cell-matrix interactions between av133 
and L1 may have important ramifications for melanoma 
progression since c~133 expression has been linked to in- 
creased tumorgenicity and invasion (Albelda et al.,  1991; 
Felding-Habermann, 1992; Albelda, 1993). 
Materials and Methods 
Reagents and Antibodies 
Integrin-specific mAbs used in these studies include LM609 (anti-avl~3, 
Cheresh and Spiro, 1987) and P3G2 (anti-ctv135,  Wayner et al., 1991). Anti- 
body P3G2 was kindly provided by Dr. E. A. Wayner (University of Min- 
nesota, Minneapolis, MN). LM609 was produced in one of our laborato- 
ries. Ll-specific mAb 5G3 was generated in our laboratory (Mujoo et al., 
1986)  and was purified with Protein-A. Control mAb W6/32 specific for 
the HLA-class I antigen was purified from ascites in this laboratory. In- 
hibitory cyclic RGD peptide 66203  (cyclo-RGDfv) and control peptide 
69601  (cyclo-RADfv) were synthesized and characterized by Drs. A. Jon- 
czyk, B. Diefenbach, and S. Goodman (E. Merck, FGR) and were kindly 
made available by Dr. D. A. Cheresh (Scripps Research Institute, La Jolla, 
CA). EGTA was purchased from Sigma Chem. Co. (St. Louis, MO). 
Cell Lines 
Human melanoma cell line M21 was derived in our laboratory as a sub- 
clone from the cell line UCLA-SO-M21 that was kindly provided by Dr. 
D. L. Morton (University of California, Los Angeles, CA). Variant av-defi- 
cient cells (M21-L), were negatively selected from M21 ceils by fluores- 
cence-activated cell sorting (FACS) with anti-av mAb LM142 (Cheresh 
and Spiro,  1987). M21-L cells were  subsequently transfected with an 
av-cDNA (Felding-Habermann et  al.,  1992).  M21-L4 cells (av-reconsti- 
tuted) and M21-L12 cells (av-deficient transfection control) were selected 
from a panel of transfected subpopulations by FACS with mAb LM142. 
J558L myeloma cells were originally obtained from the American Tissue 
Type Collection (ATCC; Rockville, MD) and were stably transfected with 
the full-length human cDNA encoding for human L1. Transfection was 
performed using the pJanusin vector (Traunecker et al., 1991; Rader et al., 
1993).  All cells were maintained in RPMI-1640 supplemented with 10% 
fetal calf serum. 
Purification  of Rat and Human L1 
Rat NILE/L1 was purified by immunoaffinity chromatography as previ- 
ously described (Lemmon et al., 1989).  Briefly, neural membranes were 
prepared from rat brains by separation on sucrose density gradients. The 
membranes were subsequently extracted with 1% deoxycholate, and the 
extract purified on a  mAb affinity column. The mAb used, 74-5H7, has 
previously been documented to be specific for mammalian L1 (Lemmon 
et al., 1989)  and was coupled to an Affi-Gel-10 support (Bio-Rad, Rich- 
mond,  CA).  NILE/L1  was eluted from the column with  0.1  M  dieth- 
ylamine (pH  11.5)  and was immediately neutralized with Tris-HCl. To 
ensure removal of any contaminating antibody eluted material was incu- 
bated with Affigel-10 beads coated with rabbit anti-mouse immunoglobu- 
lin antibodies. Human L1 was purified from M21 cell lysates essentially as 
described (Wolff et al., 1988). In brief, 4 ml of packed M21 cells were solu- 
bilized in a lysis buffer (50 mM Tris-HCl, 150 mM NaCl, containing 0.5% 
Nonidet P-40 and protease inhibitors). Insoluble material was pelleted by 
centrifugation at 100,000 g for 1 h and the supernatant passed over an im- 
munoaffinity column consisting of Ll-specific mAb 5G3 coupled  to an 
Affi-Gel-10 support (Bio-Rad).  After extensive washing, L1 was eluted 
from the column with 0.1 M diethylamine (pH 11.5) and was immediately 
neutralized with Tris-HCI. The purity of L1  preparations was judged on 
the basis of SDS-PAGE and silver staining. 
Construction  and Expression  of L1 Fusion Proteins 
The generation and characterization of L1  fusion proteins used in this 
study has been described (Zhao and Siu, 1995). In brief, three eDNA frag- 
ments coding for Ig-like domains 1, 2, and 3 (Ig 1-3), Ig-like domains 4, 5, 
and 6 (lg 4-6) and for all five fibronecfin type-III-like repeats (FN 1-5) 
were  prepared  and  inserted  between  the  EcoRI  and  BamHI  sites of 
pGEX-3X. The eDNA fragment Ig 1-3 codes for amino acids between po- 
sitions 24 to 351, the eDNA fragment Ig 4-6 codes for amino acids be- 
tween positions 352 and 595, and the eDNA fragment FN 1-5 codes for 
amino acids between positions 596 and 1094 (amino acid numbering ac- 
cording to Hlavin and Lemmon, 1991).  In all three cases, GST was fused 
to the amino terminus of the fusion protein. To produce GST-L1 fusion 
proteins, transformed Escherichia coli strain JM101 was induced by add- 
ing 1 mM isopropyl 13-D-thiogalactopyranoside (IPTG) and the induced 
bacteria subsequently resuspended in a lysis buffer (50 mM Hepes buffer, 
5% glycerol, 2 mM EDTA, 0.1 M DTT, pH 7.9). Fusion proteins were iso- 
lated from inclusion bodies, solubilized and refolded as described (Zhao 
and  Siu,  1995).  A  second eDNA  fragment was constructed coding for 
amino acids inclusive of Ig-like domains 3 through 6 (amino acids between 
positions 223  and 685). An oligonucleotide primer (sense, 5' ATI" GAC 
AGG AAT TTC CGC CTG CTC TI'C CCC ACC 3'; anti-sense, 5' TGT 
GAC CAC AGT CCT CGA GAC CGG GCT GGG CTC 3') was used to 
amplify this eDNA and introduced 5' a restriction site for EcoRl and 3' a 
recognition site for XhoI. After amplification the PCR products were di- 
gested with EcoRI and Xhol and ligated into a similarly treated prokary- 
otic expression vector pGEX-5X-3. The sequence of the resulting plasmid 
was confirmed. TKX1 cells were transformed with these plasmids and pro- 
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used to reduce the formation of inclusion bodies and thereby facilitate pu- 
rification under non-denaturing conditions. All GST-fusion proteins were 
subsequently purified  by affinity chromatography using a  glutathione- 
Sepharose 4B and were extensively dialyzed against PBS. L1-GST fusion 
proteins were analyzed by SDS-PAGE and are described by Zhao and Siu 
(1995). 
The RGD site within Ig-like domain 6 in the fragment coding for amino 
acids inclusive of Ig-like domains 3 through 6 was mutated into a  DVD 
site by inverse PCR mutagenesis (Hemsley et al., 1989). PCR amplifica- 
tion using this cDNA in pGEX-5X-3 as a template was performed in 10 
mM Tris-HCl, 50 mM KC1, 0.01% gelatin, 0.05% NP-40, 2 mM MgC12, 0.2 
mM deoxynucleotide triphosphate  with  2.5  U  Pfu and  1  U  Taq  poly- 
merase, and 1 ixM sense and anti-sense 5' oligonucleotide primers. The 
primers used were: sense 5' CCC AGC ATC ACC TGG GAC GTC GAC 
GTC GAC GGT CGA GAC CTC GTC 3'; anti-sense, 5'  CTG CAA 
GGA GGG GTC AAA GGA GGC CTG GCA CGT GAA GGT 3'. The 
sense primer introduced an AatI1 restriction site. After PCR amplification 
the resulting product was treated with Klenow fragment of DNA poly- 
merase to remove extra nucleotides possibly added at the 3' end and sub- 
sequently blunt ligated. The ligation product was transformed into TKX-1 
ceils. The newly introduced AatlI restriction site facilitated screening for 
sucessfuUy  mutated clones. The sequence of these was confirmed. 
Characterization of  L1 Expression 
Levels of L1 expression on M21  melanoma cells or on J558L myeloma 
cells transfected with L1 cDNA were determined by FACS analysis with 
Ll-specific mAb 5G3  (Mujoo et al.,  1986).  Subconfluent cultures were 
harvested and stained with this mAb at  10 p.g/ml.  The cells were then 
treated with an anti-mouse IgG FITC-conjugated antibody and were ana- 
lyzed  with  a  FACscan  flow  cytometer  (Becton  Dickinson,  Mountain 
View, CA).  Control cells were  treated  with nonspecific isotype control 
mAbs. L1 shed by M21 melanoma cells was further characterized by im- 
munoblot analysis of melanoma-conditioned media. Concentrated cell-free 
conditioned media were  analyzed by sodium dodecyl sulfate-polyacryl- 
amide gel electrophoresis (10% acrylamide) and subsequent immunoblotting 
with Ll-reactive polyclonal antibody 6096. This antibody was kindly provided 
by Dr. J. Hemperly (Becton Dickinson, Research Triangle Park, NC). 
Adhesion Assays 
Adhesion experiments were performed as detailed by Lagenaur and Lem- 
mon (1987)  with some modifications. Purified L1  ligands were  spotted 
into the center of the wells of 96-well Titertek plates (ICN Flow, Aurora, 
OH) in 1 ixl of PBS and the ligands subsequently air dried onto the plastic. 
Unless otherwise stated, an optimal concentration of 75-100 ng/mm  z was 
used. After drying, treated and control wells were blocked with 5% BSA 
for 3 h  at 37°C.  Unless otherwise stated, cells were then added and al- 
lowed to adhere for 90 min at 37°C. The cells were added as a single cell 
suspension at 1 x  105/well. At this cell number, the cells formed a mono- 
layer over the bottom of each well and in the absence of rotation did not 
tend to aggregate. The cells were maintained in fibroblast basal medium 
(FBM; Clonetics, San Diego, CA) supplemented with 1% BSA. To opti- 
mize binding this adhesion buffer was also supplemented with 0.4 mM 
MnC12. At the end of the assay the wells were carefully washed, and non- 
adherent cells were removed under a constant vacuum. Remaining adher- 
ent eeUs were fixed with 4% paraformaldehyde and enumerated with the 
aid of an inverted light microscope. Ceils were counted per unit area using 
a  20×  high powered  objective and an ocular grid.  Experimental treat- 
ments were performed in triplicate with a minimum of four areas counted 
per well. For inhibition studies, the cells were pretreated with mAbs (40 
p.g/ml) or peptides (20 ~g/ml) for 30 min before the addition of both cells 
and inhibitors to preprepared  wells.  EGTA was added  to some of the 
wells at 5 mM. 
Migration Assay 
Migration assays were performed with 24-well Transwell plates (Costar 
Corp., Cambridge, MA) essentially as described (Leavesley et al., 1992). 
Each well in a Transwell plate consists of an upper chamber or insert (6.5- 
mm diam) separated from a lower chamber by a polycarbonate membrane 
containing 8.0-pxm pores. This size of pore allows the directed migration of 
melanoma cells from the upper to lower chambers. To test for haptotactic 
migration, L1 ligand was air dried onto the underside of membranes of in- 
verted inserts at ~100 ng/mm  2. M21 cells were subsequently added to up- 
per chambers at  1  ×  l0  s cells per chamber in FBM supplemented with 
0.5% BSA and 0.4 mM MnCI  2. After 18 h, directed migration of cells from 
upper to lower chambers was quantified by enumerating the number of 
cells both at the bottom of the lower chambers and associated with the un- 
dersides of membranes. For inhibition studies, mAbs were added at 40 txg/ 
ml to both the lower and upper chambers. 
Tissue Immunofluorescence 
To generate primary tumors, M21 melanoma cells were injected subcuta- 
neously into the flank of female C.B.17 scid/scid  mice. Each mouse re- 
ceived 2 x  106 cells in 100 p.l of PBS. After approximately four weeks the 
primary tumors (>2  mm in diameter) were  resected and sectioned for 
staining with Ll-specific mAb 5G3 and with a laminin-specific rabbit poly- 
clonal antibody (Serotec Ltd., Oxford, UK). Before staining, frozen sec- 
tions were fixed with  acetone and preblocked with 5%  BSA. Sections 
were then stained with a mixture of Ll-specific mAb 5G3 (40 p.g/ml) and 
anti-laminin antibody (1/350 dilution). Murine mAb 5G3 was detected us- 
ing a 1/50 dilution of a goat F(ab')2 anti-mouse Ig-Rhodamine conjugate, 
while rabbit Ig was detected with a  1150 dilution of a  goat F(ab')2 anti- 
mouse [g-fluorescein conjugate. Both conjugates were absorbed against 
human proteins. The tissue sections were visualized and photographed us- 
ing an Olympus BX60F fluorescence microscope equipped with a  UPlan 
Apo 20x objective. 
Results 
Characterization of  L1 Expression and Immunopurified 
L1 Ligands 
Expression of L1 on the surface of human M21 cells was 
assessed with Ll-specific mAb 5G3. FACS  analysis with 
this mAb confirmed the presence of significant amounts of 
L1 on the surface of these cells (Fig. 1 A). L1 immunopuri- 
fied from M21 cell lysates was mainly evident as a single 
band  of ~215  kD  after SDS-PAGE  and  silver staining 
(Fig. 2, lane 2). L1 of this molecular mass is consistent with 
that described for L1 derived from other neuroectodermal 
tumor  cell lines  (Mujoo  et  al.,  1986;  Linnemann  et  al., 
1989). Minor L1 products were also detected at ~190 and 
80 kD. L1 fragments with this molecular mass have also 
been described and  are  proposed to represent naturally 
occurring posttranslational  cleavage products  (Mujoo et 
al., 1986; Sadoul et al., 1988). In addition to membrane-asso- 
ciated L1, we also detected significant amounts of L1  in 
M21 tumor-conditioned media. Western blot analysis with 
Ll-specific antisera showed this shed L1 to be a high mo- 
lecular mass component (>200 kD)  together with lower 
molecular mass cleavage products (Fig. 2, lane 3). Quanti- 
fication of this material by immunodot blot analysis and 
scanning densitometry confirmed the presence of soluble 
L1 and indicated shedding at the rate of ,--~250 rig/1  x  106 
cells over a 72-h period (data not shown). 
Rat NILE/L1 was purified from brain tissue. On SDS- 
PAGE this immunopurified material was evident as three 
components of ~200, 140, and 80 kD (Fig. 2, lane 1). De- 
tection of immunopurified NILE/L1  at  these  molecular 
masses is consistent with previous reports (Kobayashi et 
al.,  1992; Miura et al.,  1992).  As described for human L1, 
the lower molecular mass products represent naturally oc- 
curring posttranslational cleavage products (Sadoul et al., 
1988). 
As an experimental system to test for Ll-dependent in- 
teractions we exploited Ll-negative J558L myeloma cells 
transfected with a cDNA encoding for full length human 
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Figure I.  Expression of L1 on M21 melanoma cells (A) or J558L 
myeloma cells transfected with human L1 cDNA (B). Levels of 
L1 expression were determined by flow cytometric analysis with 
Ll-specific mAb 5G3.  Cells  were  harvested  and  stained  with 
mAb 5G3 at 10 ~g/ml. The cells were then treated with an anti- 
mouse  IgG FITC-conjugated  antibody  and  analyzed  using  a 
FACscan flow cytometer (Becton Dickinson, Mountain View, CA). 
Control cells were treated with a nonspecific isotype control mAb. 
L1. To confirm expression of L1 by transfected J558L my- 
eloma cells, flow cytometric analysis was performed with 
Ll-specific  mAb  5G3.  The  transfected  J558L  myeloma 
cells were found to express high levels of L1 in an amount 
comparable to that found on M21  cells (Fig.  1 B). Wild- 
type J558L myeloma cells were confirmed to be negative 
for L1 expression (Fig. 1 B). 
M21 Cell Adhesion to NILE ILl Is Calcium-dependent 
and Does Not Involve Homophilic L1-L1 Interaction 
Immunopurified  NILE/L1  was  directly  coated  onto  the 
bottom of 96-well plates and used for cell adhesion experi- 
ments.  M21  cells  adhered  to  the  purified  NILE/L1  in  a 
Figure 2.  Characterization of L1 immunopurified from rat brain 
(lane  1) or from M21  cell lysate  (lane 2). The immunopurified 
ligands  were  subject  to  7%  SDS-polyacrylamide gel  electro- 
phoresis and subsequent silver staining. L1 present in M21 condi- 
tioned media (lane 3) was detected by Western blotting with a 
Ll-reactive polyclonal antibody. 
concentration dependent fashion (Fig. 3 A). Adhesion was 
first evident after 20 min and was optimal after 1 h (Fig. 3 
B).  Taking into  account the  number of cells seeded per 
unit area, between 35-45% of the ceils seeded adhered to 
the NILE/L1  (Figs. 3 A  and 4 A).  Of the  adherent cells, 
~50%  showed  evidence  of cell  spreading  after  120  min 
(Fig. 4 B). 
To further  characterize  the  adhesion  observed,  it was 
determined  whether  the  interaction  with  NILE/L1  was 
Ca++-dependent.  Chelation of extracellular calcium with 
EGTA (5 mM) completely abrogated the M21  cell adhe- 
sion  (Figs. 4  C  and 5).  Likewise, no significant adhesion 
was observed when Car+-free HBSS was used as an adhe- 
sion  buffer  (not  shown).  However,  short  term  mainte- 
nance in the absence of Ca r+ did not affect M21 cell via- 
bility.  This  cation  dependence  argues  against  a  role  for 
homophilic  L1-L1  interaction  in  the  adhesion  observed 
since this type of interaction was documented to be Ca  r+- 
independent (Sonderegger and Rathjen, 1992). 
To determine whether this lack of homophilic L1 inter- 
action  could  be  attributed  to  the  purified  ligand  or  the 
M21  cells  themselves  we  looked  for  evidence  of Ca  rr- 
independent  adhesion by myeloma cells transfected with 
full-length human L1 cDNA. Contrary to M21 cells, these 
transfected cells did show Ca++-independent  adhesion to 
the same purified NILE/L1 glycoprotein (Fig. 5). Further- 
more this adhesion was absolutely dependent upon L1-L1 
interaction since untransfected, Ll-negative myeloma cells 
showed no evidence of adhesion  (Fig. 5). It is interesting 
to note that while M21  cells were observed to spread on 
the  purified NILE/L1, the  LI(+) myeloma cells showed 
no evidence of cell spreading even after 3 h (Fig. 4 D). Sig- 
nificantly,  heat  denaturation  of the  L1  ligand  (100°C,  10 
min) abolished LI(+) myeloma cell attachment (data not 
shown). This finding suggests that the L1 will only support 
the homophilic ligation observed when in a native confor- 
mation. Importantly, our immunopurified NILE/L1 ligand 
appears to be in a  native or close to native conformation 
that can support both homophilic L1-L1 interaction  and 
attachment of M21 cells via a heterophilic mechanism. 
Together these data indicate that melanoma cell-associ- 
ated L1 does not significantly contribute to cell adhesion, 
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Figure 3.  Adhesion  of M21  cells to immunopurified NILE/L1. 
(A) M21 cells were allowed to adhere to NILE/L1 at concentra- 
tions ranging  from 5-500  ng/mm  2.  (B)  M21  cells were seeded 
onto NILE/L1 at 250 rig/ram  2 and allowed to adhere for various 
time points.  Adherent cells were counted per unit  area with  a 
20× high powered objective. Experimental treatments were per- 
formed in triplicate  with a minimum of four areas counted per 
well. The bracketed number indicates  mean % adhesion taking 
into account the number of cells originally seeded per unit area. 
Error bars represent _+ 1 SD. 
despite  high levels of expression (Fig.  1 A). Thus, these 
melanoma cells appear to recognize and adhere to L1 ex- 
clusively through a  heterophilic interaction that is Ca  ÷+- 
dependent. 
M21 Cell Adhesion to LIlNILE Is Dependent on 
Integrin Olvfl  3 
Heterophilic interaction between members of the integrin 
family and members of the IgSF have been documented 
(Staunton et al.,  1990;  Ager and Humpheries, 1991). Re- 
cently, it has been reported that Otv~  3 can recognize PE-CAM 
(Piali et al., 1995). We therefore determined whether an etv 
integrin may also be involved in melanoma cell adhesion 
to purified NILE/L1. In this regard, it was previously doc- 
umented that M21  cells express significant levels of etv[33 
and some av[~  5 (Felding-Habermann et al.,  1992). To ad- 
dress this issue we exploited M21  cell variants either ex- 
pressing or lacking the av-integrin subunit (Felding-Hab- 
ermann  et  al.,  1992).  Thus,  adhesion  experiments  were 
performed with  wild-type O~v(+  )  M21  cells,  selected  av- 
negative  M21-L  cells,  <xv(+)  M21-L4  cells  (M21-L cells 
transfected  with  the  etv-Subunit  cDNA),  and a,-negative 
M21-L12  cells (M21-L mock transfectants).  Importantly, 
only the Otv(+  ) M21  and M21-L4 cells showed significant 
adhesion to rat NILE/L1 (Fig. 6 A). These results demon- 
strate  that  M21  cells  can  use  an  etv-integrin  to  bind  to 
NILE/L1. 
To  define  the  et  v integrin  involved,  adhesion  experi- 
ments were performed with  function  blocking mAbs to 
Otv[~  3 (LM609) and to etv~5 (P3G2). Confirming a role for 
ot,[33, adhesion was almost completely abrogated by mAb 
LM609 (Fig. 6 B). In contrast, neither mAb P3G2 or a con- 
trol binding mAb to HLA class I antigen (W6/32) signifi- 
cantly affected M21  adhesion.  Further  supporting a  role 
for Ctv[33, adhesion could also be abrogated by cyclic RGD 
peptide  66203  (cyclo-RGDfv) which  can  specifically in- 
hibit et,~3 ligation (Fig. 6 B). In contrast, control peptide 
69601  (cyclo-RADfv) did not significantly affect adhesion. 
Significantly,  while  heat  denaturation  of  the  NILE/L1 
ligand  prevented homophilic interaction  with  the  LI(+) 
myeloma cells, it did not abrogate M21 cell attachment via 
av[33 (data not shown). This would suggest that this inte- 
grin can recognize both native and denatured forms of the 
molecule. 
Optimal Adhesion and Spreading on Human L1 
Requires av~3 Ligation to an RGD Sequence in Its Sixth 
Immunoglobulin-like Domain 
Rat L1/NILE has two RGD sequences, and one of these 
sequences  is  conserved  in  man  (Hlavin  and  Lemmon, 
1991).  To determine whether ~v[~3 can still recognize hu- 
man L1 we looked for evidence of etv133-dependent  adhe- 
sion and spreading on L1 immunopurified from M21  cell 
lysates. As observed with rat L1, optimal adhesion to the 
human L1 required expression of the av-subunit (Fig. 7 A) 
while adhesion of wild-type M21  cells could be partially 
abrogated with mAb LM609 (Fig. 7 B). However, it is im- 
portant to note that the contribution of ~v[~3 to adhesion to 
human L1 was less than that to rat L1/NILE. There may 
be several explanations for this finding. First, as stated, hu- 
man L1 only has one RGD site as compared to two in rat 
L1/NILE. Secondly, it is clear that av[33 is not the only re- 
ceptor responsible for the recognition  of human  L1.  In- 
deed, we have preliminary evidence that a 131-integrin may 
also be responsible  for adhesion  to human  L1  and  to a 
lesser extent to rat L1/NILE (data not shown). It is impor- 
tant to note, however, that while LM609 only partially pre- 
vented adhesion it did have a greater impact on M21 cell 
spreading. Thus, inhibition  of cell spreading in the pres- 
ence of LM609 was greater than 60% (not shown). 
To define  the  Otvl33 binding  site within  human  L1, we 
performed a series of adhesion experiments with recombi- 
nant  Ll-fragments. Three fragments covering the  entire 
extra-cellular domain of human L1 were tested and con- 
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of M21 cells seeded onto im- 
munopurified  NILE/L1  in 
the presence (C) or absence 
(A and B) of 5 mM EGTA. 
(D)  Morphology  of  LI(+) 
J588L  transfectants  seeded 
onto NILE/L1. Adherent cells 
were photographed at 4× (A 
and C) or at 20× (B and D). 
Note that adherent M21 cells 
are  largely  confined  to  the 
circular area spotted with im- 
munopurified  NILE/L1  (A), 
and  that  adhesion  is  abro- 
gated  by  the  presence  of 
EGTA (C). Note that the M21 
cells  show  significant  cell 
spreading, while the adherent 
J558L  cells remain  rounded 
even after 180 rain (D). 
sisted of Ig-like domains 1 through 3 (Ig 1-3), Ig-like do- 
mains 4  through 6  (Ig 4-6),  and  the fibronectin-like do- 
mains 1-5 (FN 1-5). Of these fragments, the fragment Ig 
4-6 (amino acids 352-595) was most effective in supporting 
M21 cell adhesion (Fig. 8 A). Significantly, adhesion to this 
fragment was  absent  in  ot~-negative  cells (Fig.  8  B)  and 
consistent with Otvl33 ligation, attachment by wild-type M21 
cells could be abrogated by mAb LM609 (Fig. 8 C). A sec- 
ond  longer  L1  fragment  inclusive  of Ig-like  domains  3 
through 6 (Ig 3-6) was also tested in adhesion assays and 
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Figure 5.  M21 cells adhere to immunopurified  NILE/L1  via a 
heterophilic,  calcium-dependent  mechanism.  M21  cells, J588L 
cells, or J588L L1 transfectants were allowed to adhere to NILE/ 
L1 for 120 rain in the presence or absence of EGTA (5 raM). Ad- 
herent cells were counted per unit area using a 20× high powered 
objective. Experimental  treatments were performed in triplicate 
with a minimum of four areas counted per well. Error bars repre- 
sent +--1 SD. 
was  also  found to support significant M21  cell adhesion 
(Fig. 8 D). Adhesion to this fragment was also inhibited by 
mAb LM609 (data not shown). This fragment was isolated 
under conditions that did not require refolding of the pro- 
tein (refer to Materials and Methods). 
Attachment to two fragments that both include the sixth 
Ig like domain of human L1 (Ig 3-6, Ig 4-6) is consistent 
with the presence of an RGD site in the sixth Ig-like do- 
main (Hlavin and Lemmon, 1991). To confirm the impor- 
tance of this RGD site we generated a further Ig 3-6 frag- 
ment with a disrupted RGD sequence (refer to Materials 
and Methods). Consistent with RGD-dependent adhesion 
by ~tvl33 there was an almost complete loss of attachment 
to the mutated fragment (Fig. 8 D). 
Human L1 Supports Haptotactic Melanoma Migration 
via Integrin avfl3 
It is well documented that av[33 ligation can promote cell 
migration (Cheresh 1992;  Leavesley et al.,  1992).  There- 
fore, we  determined  whether  ligation  of human  L1  by 
av[33, could induce cell motility or migration. This was as- 
sessed  using  Transwell  plates  essentially  as  described 
(Leavesley et al.,  1992).  Two important findings are evi- 
dent from these studies. First, human L1 can support hap- 
totactic migration by melanoma cells (Fig. 9) and second, 
ave3 appears to play a major role in the induction of this 
migration.  Thus, mAb  LM609 reduced migration to the 
immunopurified human L1 by --,60%  (Fig. 9). However, 
the same antibody reduced adhesion by only N35% (Fig. 
7). Together these data suggest that otvl33 recognition of 
human L1 may be more important for the induction of cell 
spreading and motility than adhesion. 
The Journal of Cell Biology, Volume 132, 1996  480 < 
A 
150 
125-  l 
100  ........  .:.:.:.:.:.:.:-: 
............-... 
............... 
• .............. 
............... 
75-  :::::::::•:::::: 
.........-.... 
-............... 
50-  :':':':':':':':' 
:.:.:.:.:.:.:.:. 
................ 
25-  !i!i!iiiiiiiiiii 
+:.:.:.:.:.:-: 
,............  0 
M21 
~v(+) 
T 
.-.-.J..!-.-.-.- 
:i:i:i:i:i:i:i:~ 
!:i:i:i:i:!:i:i: 
.......,.,.,*,.. 
,..,,.,..,.,..,, 
.............-.. 
................ 
~!i~!!ii?i?!?iii 
!iiii:.i::iiiii:.i:: 
~  i::iii?:i:i: 
;:i:iiiiilili~i~  ~:.:.:.~.:.:.:., 
I  I  I 
L  L4  L12 
~v(-)  ~v(+)  ~(-) 
100" 
e~ 
O 
.~  80- 
< 
60- 
~  40- 
20- 
0- 
B 
Antibodies 
w6/32  P3G2 LM609 
P~cptides 
RAD  RGD 
Figure  6.  Adhesion  of  M21 
cells  to  immunopurified 
NILE/L1  is dependent on li- 
gation  of integrin  c~vl33. (A) 
M21 av-variants were seeded 
onto  NILE/L1  and  allowed 
to  adhere  for  120  min.  (B) 
M21  cells  were  seeded  onto 
NILE/L1  and allowed to ad- 
here  in  the presence or ab- 
sence of specific  antagonists. 
Cells  were  pretreated  with 
mAbs (40 ixg/ml) or peptides 
(20 Ixg/ml) for 30 min before 
the addition of both cells and 
inhibitors  to  preprepared 
wells.  Adherent  cells  were 
counted per unit area with a 
20×  high powered objective. 
Experimental treatments will be performed in triplicate with a minimum of four areas counted per well. Integrin-specific mAbs used in 
these studies included LM609 (anti-av133),  and P3G2 (anti-a~t35).  Control mAb W6/32 is specific for HLA-class I antigens. Peptides used 
included inhibitory cyclic RGD peptide 66203  (cyclo-RGDfv)  and control RAD peptide 69601  (cyclo-RADfv).  For inhibition studies 
results are expressed as percent inhibition relative to adhesion by untreated control cells. Error bars represent  _ 1 SD. 
L1-CAM Shed by M21 Melanoma Cells Can Be 
Detected in Tumor-associated ExtraceUular Matrix 
It is documented that L1  is shed by neuroectodermal tu- 
mors (Mujoo et al., 1986),  and that shed L1 can associate 
with elements of the ECM (Martini and Schachner, 1986; 
Poltorak et al., 1990). Ligation between avl33 and L1, could 
therefore occur between av133 (+)  cells and L1  deposited 
in the ECM. In this study we demonstrate that M21  cells 
also shed high molecular mass L1  fragments (Fig. 2, lane 
3).  Given  these  observations  we  wished  to  determine 
whether  this  shed  L1  could  bind  to  tumor-associated 
ECM. To address this question we looked for evidence of 
L1  deposition in the stroma of M21 cell tumors grown in 
scid/scid mice.  Interestingly,  staining  of M21  tumor sec- 
tions revealed good colocalization between human L1 and 
strands of intra-tumor laminin (Fig. 10). This is an impor- 
tant finding since it  suggests  that by  shedding  L1, mela- 
noma cells may be able to modify their extracellular envi- 
ronment to promote o~v[3  3 ligation. 
Discussion 
In this manuscript we describe a novel interaction between 
L1, a member of the IgSF, and the integrin avI33. We dem- 
onstrate that this interaction is dependent on av133 binding 
a single RGD sequence in the sixth Ig-like domain of hu- 
man L1. We further show that despite high levels of L1 ex- 
pression,  M21  melanoma cells  do not express  significant 
homophilic L1-L1 adhesion. 
Although L1 is described as a neural CAM, its expres- 
sion is not confined to cells of the nervous system. Indeed, 
this CAM has been described  on cells as diverse as lym- 
phocytes and intestinal epithelial cells  (Thor et al.,  1987; 
Kowitz et al.,  1992).  L1  has also been detected on trans- 
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Figure  7.  Adhesion  of M21 
cells  to  immunopurified  hu- 
man  L1  is  partially  depen- 
dent  on ligation  of integrin 
av133.  (A)  M21  av-variants 
were seeded  onto L1 and al- 
lowed  to  adhere  for 90  min. 
(B)  M21  cells  were  seeded 
onto  L1  and  allowed  to  ad- 
here  for  90  min  to  in  the 
presence  or  absence  of  spe- 
cific  mAbs.  The  cells  were 
pretreated  with  the  mAbs 
(40 i~g/ml) for 30 min before 
the addition of both cells and 
inhibitors  to  preprepared 
wells.  Adherent  cells  were 
counted per unit area  with a 
20x  high powered objective.  Experimental treatments were performed in triplicate with a minimum of four areas  counted  per well. 
mAbs used include LM609 (anti-av[33),  and control mAb W6/32  (anti-HLA-class  I). Error bars represent  _+1 SD. N.T. is ligand alone 
with no treatment. 
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Figure  8.  Adhesion of M21 cells to recombinant L1 fragments• 
(A) M21 cells were seeded onto LI fragments consisting  of Ig- 
like domains 1 through 3 (Ig l-3), Ig-like domains 4 through 6 (lg 
4-6), and fibronectin-like repeats 1 through 5 (FN 1-5) and were 
allowed to adhere for 90 min.  (B) M21 av-variants seeded onto 
Ig-like domains 4 through 6 (Ig 4-6). (C) M21 cells were seeded 
onto Ig-like domains 4 through 6 (Ig 4-6) in the presence or ab- 
sence of mAb LM609 (anti-av133), or control mAb W6/32  and 
were allowed to adhere for 90 min. The cells were pretreated with 
the mAbs (40 ~g/ml) for 30 min before the addition of both cells 
and inhibitors to preprepared wells• (D) M21 cells were seeded 
onto  a  recombinant  fragment  inclusive  of  Ig-like  domains  3 
through 6 with a mutated RGD sequence in the sixth Ig-like do- 
main. Adherent cells were counted per unit area with a 20× high 
powered objective. Experimental treatments will be performed in 
triplicate with a minimum of four areas counted per well. Error 
bars represent _+ 1 SD. N.T. is ligand alone with no treatment. 
formed cell lines of different histological origin (Mujoo et 
al.,  1986;  Linnemann  et  al.,  1989;  Reid  and  Hemperly, 
1992)• The av133 heterodimer has been reported on endo- 
thelial  cells,  fibroblasts,  smooth muscle cells, cells  of the 
immune system, and some tumor cell lines (Cheresh, 1992; 
Brooks et al., 1994). Such expression suggests that Ll-av133 
pairing  may occur between  multiple  cell  types including 
cells of the immune and nervous systems and the vascula- 
ture.  In  this  regard,  it  is  interesting  that  Hubbe  et  al. 
(1993)  have shown that  L1 can promote the  adhesion of 
murine  leukocytes to endothelial  cells  and  demonstrated 
that this interaction is calcium dependent and required an 
undefined  heterophilic  ligand.  While  Ll-otvl33 interaction 
may contribute to heterotypic or homotypic cell-cell adhe- 
sion, it may be that this interaction is more important for 
the generation of secondary responses relating to cell mo- 
tility, survival and growth. Thus, in addition to promoting 
cell adhesion, otv~  3 is documented to promote cell migra- 
tion  (Leavesley  et  al.,  1992),  suppress  apoptosis  (Mont- 
gomery et al., 1994), and stimulate mitogenesis (Sanders et 
al., 1992). 
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Figure 9.  Haptotactic migration of M21 cell to human L1. L1 was 
coated onto the underside of membranes of Transwell inserts at 
~100  ng/mm  2.  M21  cells  were  subsequently  added  to  upper 
chambers at 1 ×  105 cells per chamber and after 18 h the directed 
migration of cells from upper to lower chambers quantified  by 
enumerating the number of cells both at the bottom of the lower 
chambers  and  associated  with  the  undersides  of membranes. 
mAb LM609 (anti-av133) and control mAb W6/32 were added at 
40 ixg/ml to both the lower and upper chambers. Treatments were 
performed in duplicate. Error bars represent -+ 1 SD. 
The interaction between  L1 and  Otv~  3 may have signifi- 
cant ramifications for the progression of malignant mela- 
noma and other LI(+) tumors• In this regard, expression 
of av133 has been directly linked to melanoma progression 
(Albeda et  al.,  1991; Felding-Habermann,  1992; Albelda, 
1993; Montgomery et al., 1994). Significantly, the same av - 
negative M21 variants used in this study, have been shown 
to  be  significantly  less  tumorigenic  in  the  skin  of nude 
mice than their av (+) counterparts  (Felding-Habermann, 
1992)•  We  have previously reported  that  the  capacity of 
avl33 to promote neoplastic progression may be linked to 
its  ability  to  promote  tumor  cell  survival  and  growth 
(Montgomery  et  al.,  1994).  Interestingly,  L1  expression 
has also been linked to melanoma progression• Thus, Lin- 
nemann  et  al.  (1989)  describe  L1  expression  on a  meta- 
static variant of the melanoma cell line K1735, while non- 
metastasizing K1735 cells were found to be negative• 
In addition to promoting interaction between cells it is 
also conceivable that ligation may occur between avl33 (+) 
cells and L1 deposited in the ECM. In this respect, L1 may 
have a dual function both as a CAM and a substrate adhe- 
sion  molecule  (SAM).  In  support  of  this  concept  we 
present evidence that M21 cells shed high molecular mass 
L1 fragments and demonstrate L1 immunoreactivity in the 
stroma of M21 tumors• In this regard, a number of studies 
have described incorporation of shed L1 into the occlud- 
ing ECM. In the adrenal medulla, for example, L1 immu- 
noreactivity has been found in the ECM adjacent to chro- 
maffin cells (Poltorak et al., 1990). Martini and Schachner 
(1986)  have  reported  L1  expression  in  basement  mem- 
branes associated with murine Schwann cells and in associ- 
ation  with  collagen  fibrils  of  the  endoneurium.  Given 
these  observations,  it  is conceivable that by shedding L1 
tumors can modify their immediate extracellular environ- 
The Journal of Cell Biology. Volume  132,  1996  482 Figure 10.  Colocalization  of shed L1 and laminin in the stroma of a M21 tumor. A primary tumor generated in an immunodeficient 
mouse was resected, sectioned  and stained  for both laminin (A) and L1 (B). L1 was detected using human Ll-specific mAb 5G3. The 
laminin was detected using a laminin-specific rabbit polyclonal antibody (Serotec,  UK). Murine  mAb 5G3 was labeled using a human 
absorbed goat F(ab')2 anti-mouse Ig-Rhodamine conjugate, while the rabbit Ig was labeled using a human absorbed goat F(ab')2 anti- 
mouse Ig-fluorescein  conjugate.  Tumor sections were visualized and photographed using an Olympus BX60F fluorescent  microscope 
and a UPlan Apo 20× objective. To further demonstrate colocalization, fluorescein and rhodamine fluorescence  was merged (C). Colo- 
calization is evident as yellow colorization. Note that laminin is evident as strands within the tumor stroma (A), while L1 is evident both 
on the M21 cells and in association with the strands of laminin (B and C). 
ment  to  promote  av133 ligation.  While  we  demonstrate 
good colocalization between L1  and intra-tumor laminin 
we cannot claim on the basis of these data alone that direct 
ligation occurs between these ligands. However, it is inter- 
esting that an Ll-related molecule in the chick (Ng-CAM) 
has been shown to bind to the short arms of laminin (Gru- 
met et al.,  1993a).  It is also of interest  that L1  has been 
shown  to  interact  with  matrix  chrondroitin  sulfate  pro- 
teoglycans (Grumet et al., 1993b; Friedlander et al., 1994). 
Molecular cloning and sequencing of human and rat L1 
has demonstrated the presence of a single RGD sequence 
that is conserved between both species (Hlavin and Lem- 
mon,  1991;  Miura et al.,  1991).  Our findings suggest that 
conservation  of this  sequence  may reflect  its  functional 
significance as a binding site for av133. Accepting that this 
RGD site is important for integrin recognition, one would 
expect it to be accessible in the native molecule. To test 
this we performed a structural analysis based on the docu- 
mented sequence of the sixth Ig-like domain of human L1 
(Hlavin and Lemmon, 1991).  By analogy to known struc- 
tures of other C2 type Ig-like domains (Williams and Bar- 
clay, 1988; Rao et al., 1993), the RGD sequence in Ig-like 
domain 6 of L1 may correspond to the C'-E loop (data not 
shown).  Since this  region of the  L1  molecule has a  high 
density of charged residues it is expected that this loop will 
be exposed to the external aqueous environment and thus 
be available for integrin interaction.  The findings  of our 
structural  analysis  are  similar to  those  recently reported 
for the interaction between the integrin VLA-4 and Ig-like 
molecule VCAM-1,  in  which  the  integrin  was  shown  to 
recognize an exposed C-D loop region (Wang et al., 1995). 
Denaturation experiments suggest that av133 can recog- 
nize  L1  in  either  a  native  or  denatured  state  (data  not 
shown). This is consistent with the fact that av133 can also 
recognize either native or denatured  vitronectin  (unpub- 
lished  observation). This is  an important finding since it 
suggests Otv~  3 may be able to recognize forms of L1  that 
have been denatured as a result of proteolysis. In this re- 
gard, L1  cleavage products have been described  both in 
the  ECM and  tightly associated with the cell membrane 
(Sadoul et al., 1988). Recognition of denatured L1 may be 
particularly important in the context of melanoma, since 
these  transformed cells generally express  increased  pro- 
teolytic activity. 
Given the presence of two RGD sites in rat NILE/L1 we 
cannot exclude recognition of both by this integrin. Indeed 
such an interaction may explain why we observed greater 
av133-dependent adhesion on rat L1 than on its human ho- 
mologue. It is important to emphasize that a component of 
M21 cell binding to L1 could not be abrogated with antag- 
onists of av133. Thus, it is probable that other heterophilic 
ligands  are capable of recognizing L1. In this regard, we 
have  some  preliminary  evidence  that  a  131-integrin  may 
also  be involved.  However, the  131-heterodimer involved 
remains to be defined. Since RGD-dependent adhesion is 
not exclusively a  property of avl3  s we do not exclude the 
possibility that other integrins may also display RGD de- 
pendent adhesion to L1. The extent and nature of integrin 
involvement may ultimately vary according to cell type. 
It is important to note that while transfected LI(+) my- 
eloma cells displayed significant homophilic adhesion on 
immunopurified L1/NILE, such an interaction was not ob- 
served with the M21 melanoma cells. This was the case de- 
spite the fact that both cell lines expressed high levels of 
L1.  A  reduction  in  L1-L1  adhesion  in  transformed cells 
may reduce cohesion in the primary tumor and thus pro- 
mote metastasis. In this regard, an interesting parallel may 
be  drawn  between  our  findings  and  those  reported  for 
NCAM.  Thus,  NCAM  is  likewise  expressed  on  many 
highly malignant tumors and most significantly, due to ei- 
Montgomery et al. L1 Is a Ligand  for lntegrin av~  3  483 ther alternative mRNA splicing or posttranslational modi- 
fications, tumor-associated NCAM has a reduced capacity 
for  adhesive  homophilic  interactions  (Moolenaar  et  al., 
1992). The mechanism(s) regulating the adhesive potential 
of  L1-L1  interactions  remains  to  be  determined.  How- 
ever, it is interesting to note that melanoma cells express 
an alternative form of L1 that has a four amino acid dele- 
tion (RSLE) within the cytoplasmic region (Kobayashi et 
al., 1991). In contrast, this sequence is present in the L1 ex- 
pressed by the transfected J558L myeloma  cells that did 
express  significant homophilic L1-L1  adhesion.  While  a 
homophilic L1-L1  interaction did not appear to support 
significant melanoma adhesion we do not exclude the pos- 
sibility that this interaction may still occur at a level that 
can promote signal transduction. 
Documented  interactions between integrins and mem- 
bers  of  the  IgSF  include  those  between  VCAM-1  and 
VLA-4,  between  ICAM-1/2  and LFA-1  (Staunton et al., 
1990; Ager and Humpheries,  1991), and that recently re- 
ported  between  Otv~ 3  and  PE-CAM  (Piali  et  al.,  1995). 
Here  we  have  described  an additional novel pairing be- 
tween tXv133  and the neural cell adhesion molecule L1. The 
consequences of etvl33 ligation are diverse and include the 
regulation  of cell  adhesion,  migration,  survival,  growth, 
and differentiation.  Identification of L1  as a heterophilic 
ligand for otv133 suggests a role for L1 that may go beyond 
those currently described during neurological development. 
The authors wish to thank L. Oliva, B. Gillis, and G. Cheng for their ex- 
cellent technical support. 
This study was supported by National Institutes of Health Outstanding 
Investigator grant CA42508  (R. A. Reisfield)  and by Medical  Research 
Council (MRC)  funding (Canada, C.-H. Siu). X. Zhao is supported by a 
studentship award from MRC (Canada). This study was also supported in 
part by a  Young Investigator's  Award from the Pediatric Brain Tumor 
Foundation of the United States (A. M. P. Montgomery). 
This is Scripps manuscript 9637-IMM. 
Received  for publication 21  September  1995  and in revised form 7  No- 
vember 1995. 
References 
Ager, A., and M. L. Humphries.  1991.  Integrin alpha 4  beta 1: its structure, 
ligand binding specificity and role in lymphocyte-endothelial cell interac- 
tions. Chem. Immunol. 50:50-74. 
Albelda, S. M. 1993. Role of integrins and other cell adhesion molecules in tu- 
mor progression and metastasis. Lab. Invest. 68:4-17. 
Albelda, S. M., S. A. Mette, D. E. Elder, R. Stewart, L. Damjanovich, M. Her- 
lyn, and C. A. Buck. 1991. Integrin distribution in malignant melanoma: as- 
sociation of the 133 subunit with tumor progression. Cancer Res.  50:6757- 
6764. 
Bock, E. C., C. Richter-Landsberg, A. Faissner, and M. Schachner. 1985. Dem- 
onstration of immunochemical identity between the nerve growth factor- 
inducible large external (NILE) glycoprotein and the cell adhesion molecule 
L1. EMBO (Eur. Mol. Biol. Organ.) J. 4:2765-2768. 
Brooks, P. C., A. M. P. Montgomery, M. Rosenfeld, R. A. Reisfeld, T. Hu, G. 
Klier, and D. A. Cheresh. 1994. Iutegrin Otv[~  3 antagonists promote tumor re- 
gression by inducing apoptosis of angiogenic vessels. Cell. 79:1-20. 
Cheresh, D. A. 1992. Structural and biological properties of integrin mediated 
cell adhesion. Lab. lmmunol. 12:217-236. 
Cheresh, D. A., and R. C. Spiro. 1987. Biosynthetic and functional properties of 
an Arg-Gly-Asp-directed receptor involved in human melanoma ceil attach- 
ment to vitronectin, fibrinogen and von Willebrand factor. J.  Biol.  Chem. 
262:17703-17711. 
Clyman, R. J., F. Mauray, and R. H. Kramer. 1992.131 and 152 integrins have dif- 
ferent roles in the adhesion and migration of vascular smooth muscle cells on 
extracellular matrix. Exp. Cell Res. 200:272-284. 
Felding-Habermann, B., B. M. MueUer, C. A. Romerdahl, and D. A. Cheresh. 
1992. Involvement of iutegrin av-gene expression in human melanoma tu- 
morigenicity.  Z  Clin. Invest. 89:2018--2022. 
Felsenfeld, D. P., M. A. Hynes, K. M. Skoler, A. J. Furley, and T. M. Jessell. 
1994.  TAG-1  can mediate homophilic binding, but neurite outgrowth on 
TAG-1 requires an Ll-like molecule and 131 integrins. Neuron. 12:675-690. 
Friedlander, D. R., P. Miler, L. Karthikeyan, R. K. Margolis, R. U. Margolis, 
and M. Grnmet. 1994. The neuronal chondroitin sulfate proteoglycan neuro- 
can binds to the neural cell adhesion molecules Ng-CAM/L1/NILE and 
N-CAM, and inhibits neuronal adhesion and neurite outgrowth. J. Cell Biol. 
125:669--680. 
Grumet, M., S. Hoffman, C. M. Chuong, and G. M. Edelman. 1984. Polypeptide 
components and binding functions of neuron-gila cell adhesion molecules. 
Proc. Natl. Acad. Sci.  USA. 81:7989-7993. 
Grnmet, M., D. R. Friedlander, and G. M. Edelman. 1993a.  Evidence for the 
binding of Ng-CAM to laminin. Cell Adhes. Commun. 1:177-190. 
Grnmet, M., A. Flaccus, and R. U. Margolis. 1993b. Functional characterization 
of chondroitin sulfate proteoglyeans of brain: interactions with neurons and 
neural cell adhesion molecules. J. Cell Biol. 120:815-824. 
Hemsley, A., N. Anaheim, M. D. Toney, G. Cortopassi, and D. J. Galas. 1989. 
A  simple method for the site directed mutagenesis using the polymerase 
chain reaction. Nucleic Acid Res. 17:6545--6551. 
Hlavin, M. L., and V. Lemmon. 1991. Molecular and functional testing of hu- 
man L1CAM: an interspeeies comparison. Genomics. 11:416--423. 
Hubbe, M., A. Kowitz, V. Schirrmacher, M. Schachner, and P. Altevogt. 1993. 
L1 adhesion molecule on mouse leukocytes: regulation and involvement in 
endothelial cell binding. Eur. J. lmmunol. 23:2927-2931. 
Kobayashi, M., M. Miura, H. Asou, and K. Uyemura. 1991. Molecular cloning 
of cell adhesion molecule L1  from human nervous tissue: a comparison of 
the primary sequences of L1 molecules of different origin. Biochem.  Bio- 
phys. Acta. 1090:238-240. 
Kobayashi, M., T. Mizuki, A. Wada, and F. lzumi. 1992. Cell-cell contact modu- 
lates expression of cell adhesion molecule L1 in PC12 cells. Neuroscience. 49: 
437--441. 
Kowitz, A., G. Kadmon, M. Eckert, V. Schirrmacher, M. Schachner, and P. AI- 
tevogt. 1992. Expression and function of the neural cell adhesion molecule 
L1 in mouse leukocytes. Eur. Z  lmmunol. 22:1199-1205. 
Kuhn, T. B., E. T. Stoeckli, M. A. Condrau, F. G. Rathjen, and P. Sonderegger. 
1991. Neurite outgrowth on immobilized Axonin-1 is mediated by a hetero- 
philic interaction with LI(G4). Z  Cell Biol. 115:1113-1126. 
Kujat, R., F. Miragall, D. Krause, R. Dermietzel, and K. H. Wrobel. 1995. Im- 
munolocalization of the neural cell adhesion molecule L1 in non-proliferat- 
ing epithelial cells of the male urogenital tract. Histochem.  Cell Biol.  103: 
311-321. 
Lagenaur, C., and V. Lemmon. 1987. An L-l-like molecule, the 8D9 Antigen, is 
a  potent  substrate for neurite extension. Proc.  NatL  Acad.  Sci.  USA.  84: 
7753-7757. 
Leavesley, D. I., G. D. Ferguson, E. A. Wayner, and D. A. Cheresh. 1992. Re- 
quirement of the integrin 133 subunit for carcinoma cell spreading or migra- 
tion on vitronectin and fibrinogen. Z  Cell Biol. t17:1101-1107. 
Lemmon, V., and S. McLoon. 1986. The appearence of an Ll-like molecule in 
the chick visual pathway. J. Neuroscience. 6:2987-2994. 
Lemmon, V., K. L. Farr, and C. Lagenaur. 1989. L-l-mediated axon outgrowth 
occurs via a homophilic binding mechanism. Neuron. 2:1597-1603. 
Linnemann, D., A. Raz, and E. Bock. 1989. Differential expression of cell adhe- 
sion molecules in variants of the K1735 melanoma cells differing in meta- 
static capacity. Int. J. Cancer. 43:709-712. 
Lindner, J., F. G. Rathjen, and M. Schachner. 1983. L-1 mono- and polyclonal 
antibodies modify cell migration in early postnatal mouse cerebellum. Na- 
ture (Lond.). 305:427-430. 
Martini, R., and M. Schachner. 1986. Immunoelectron microscopic localization 
of  neural  cell adhesion  molecules (L-l,  N-CAM,  and  MAG)  and  their 
shared carbohydrate epitope and myelin basic protein in developing sciatic 
nerve. J. Cell Biol. 103:2439-2448. 
Miura, M., M. Kobayashi, H. Asou, and K. Uyemura. 1991. Molecular cloning 
of cDNA encoding the rat neural cell adhesion molecule L1. FEBS Lett. 289: 
91-95. 
Miura, M., M. Kobayashi, and K. Uyemura. 1992. Fuctional expression of a full- 
lenth cDNA coding for rat neural cell adhesion and migration of cerebellar 
neurons. J. Biol. Chem. 267:10752-10758. 
Moolenaar, C. E. C.,  C. Pieneman, F. S. Walsh, W. J. Mooi, and R. J. A. M. 
Michalides.  1992.  Alternative splicing of  neural  cell adhesion  molecule 
mRNA in human small cell lung cancer cell line H69. Int. J.  Cancer. 51:238- 
243. 
Moos, M., R. Tacke, H. Scherer, D. Peplow, K. Frtih, and M. Schachner. 1988. 
Neural adhesion molecule L1  as a member of the immunoglobulin super- 
family with binding domains similar to fibronectin. Nature (Lond.). 334:701- 
703. 
Montgomery, A. M. P., R. A. Reisfeld, and D. A. Cheresh. 1994. Integrin ~v133 
rescues melanoma ceils from  apoptosis in three-dimensional dermal col- 
lagen. Proc. Natl. Acad. Sci.  USA. 91:8856--8860. 
Mujoo, K., R. C. Spiro, and R. A. Reisfeld. 1986. Characterization of a unique 
glycoprotein antigen expressed on  the  surface  of  human  neuroblastoma 
cells. J. BioL Chem. 261:10299-10309. 
Piali, L., P. Hammel, C. Uherek, F. Bachmann, R. H. Gisler, D. Dunon, and 
B. A. Imhof. 1995. CD31/PECAM-1 is a ligand for av133 integrin involved in 
adhesion of leukocytes to endothelium. J. Cell BioL 130:451-460. 
Poltorak, M.,  K.  Shimoda, and W.  J.  Freed.  1990.  Cell adhesion molecules 
(CAMs) in adrenal medulla in situ and in vitro: enhancement of chromaffin 
The Journal of Cell Biology, Volume 132, 1996  484 cell LUNg-CAM expression by NGF. Exp. Neurology.  110:52-72. 
Rader, C., E. T. Stoeckli, U. Ziegler, T. Osterwalder, B. Kunz, and P. Sondereg- 
ger. 1993. Cell-cell adhesion by homophilic interaction of the neuronal rec- 
ognition molecule axonin-1. Eur. Z  Biochem. 215:133-141. 
Rao, Y., X. F. Wu, P. Yip, J. Gariepy, and C. H. Siu. 1993. Structural character- 
ization of a homophilie binding site in the neural cell adhesion molecule. J. 
Biol.  Chem. 268:20630-20638. 
Rathjen, F.  G., and M. Schachner.  1984.  Immunocytological and biochemical 
characterization of a  new neuronal cell surface  component  (LI  antigen) 
which is involved in cell adhesion. EMBO (Eur. Mol.  Biol.  Organ.) Z 3:1-10. 
Reid, R. A., and J. J. Hemperly. 1992. Variants of human L1 cell adhesion mol- 
ecule arise through alternate splicing  of RNA. J. Mol. Neurosci.  3:127-135. 
Sadoul, K., R. Sadoul, A. Faissner, and M. Schachner. 1988. Biochemical char- 
acterization of different molecular forms of the neural cell adhesion mole- 
cule L1. J. Neurochem. 50:510-521. 
Sanders, L. C.,  B.  Felding-Habermann, B.  M.  Mueller, and D.  A. Cheresh. 
1992. Role of etv integrins and vitronectin in human melanoma cell growth. 
Cold Spring Harbor Symp. Quant.  Biol.  LVII:233-240b. 
Sonderegger, P. R., and F. G. Rathjen. 1992. Regulation of axonal growth in the 
vertebrate nervous system by interactions between glycoproteins belonging 
to two subgroups of the immunoglobulin superfamily. J. Cell Biol.  119:1387- 
1394. 
Stannton, D. E., M. L. Dustin, H. P. Erickson, and T. A. Springer. 1990. The ar- 
rangement of the irnmunoglobulin-like  domains of ICAM-1 and the binding 
sites for LFA-1 and rhinovirus. Cell. 61:243-254. 
Thor, G., R. Probstmeier, and M. Schachner. 1987. Characterization of the cell 
adhesion molecules L1, N-CAM and J1 in the mouse intestine. EMBO (Eur 
Mol. Biol.  Organ.) Z 6:2581-2586. 
Traunecker, A., A. Lanzavecchia, and K. Karjalainen. 1991. Bispecific single 
chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected 
cells. EMBO (Eur. Mol. Biol.  Organ.) J. 10:3655-3659. 
Wang, J.-H., R. B. Pepinsky, T. Stehle, J.-H. Liu, M. Karpusas, B. Browning, 
and L. Osborn.  1995.  The crystal structure of an N-terminal two domain 
fragment of vascular cell adhesion molecule 1 (VCAM-1): a cyclic peptide 
based on the domain 1 C-D loop can inhibit VCAM-I-a4 integrin interac- 
tion. Proc. Natl. Acad. Sci. USA. 92:5714-5718. 
Wayner, E. A., R. A. Orlando, and D. A. Cheresh. 1991.  lntegrins c~v~3 and 
ctvl35 contribute to cell attachment to vitronectin but diferentially distribute 
on the cell surface. J. Cell Biol.  113:919-929. 
Williams, A.  F.,  and A. N.  Barclay 1988.  The  immunoglobulin superfamily- 
domains for cell surface recognition. Annu. Rev. hnmunol. 6:381-405. 
Wolff, J.  M.,  R.  Frank,  K.  Mujoo,  R.  C.  Spiro,  R.  A.  Reisfeld, and F.  G. 
Rathjen.  1988.  A  human glycoprotein related to the mouse cell adhesion 
molecule L1. Z Biol.  Chem. 263:11943-11947. 
Zhao, X., and C.-H. Siu, 1995.  Co-localization of the homophilic binding site 
and the neuritogenic activity of the cell adhesion molecule L1 to the second 
Ig-like domain. J. Biol. Chem. In press. 
Montgomery et al. L1 Is a Ligand for Integrin ctv~  ~  485 